The FDA moved to shrink clinical trial reporting lags by launching a pilot approach to review data in real time as it is accrued. The agency said it will start with oncology studies run by AstraZeneca and Amgen, supported by a real-time data platform from Paradigm Health, and asked for public input on a broader safety-monitoring and dose-selection framework using AI. Separately, the FDA also outlined a plan to collect and review clinical trial data in real time, building on proof-of-concept efforts already underway. The approach is aimed at giving FDA scientific reviewers earlier visibility into emerging safety signals and trial performance, potentially tightening the feedback loop between sponsors and regulators. For sponsors, the next phase will be how quickly real-time submissions can be operationalized alongside protocol amendments and data quality controls. For developers, it also raises expectations around the speed of downstream analytic workflows and documentation that traditionally followed after database lock.